NCT03950609 2026-03-19
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT03070301 2024-10-10
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01678664 2024-09-25
EVACEL
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT06472388 2024-06-25
EVENET
AC Camargo Cancer Center
Phase 2 Recruiting
NCT02113800 2020-10-28
EVINEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT02315625 2020-09-09
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00688623 2019-01-25
RAMSETE/CDE16
Novartis
Phase 2 Completed
NCT01374451 2016-12-20
COOPERATE-2
Novartis
Phase 2 Terminated
NCT01628913 2016-04-07
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Novartis
Phase 2 Terminated
NCT00363051 2013-05-10
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Novartis
Phase 2 Completed